Company Overview of Bio-Cancer Treatment International Ltd.
Bio-Cancer Treatment International, Ltd. operates as a biotech company in Hong Kong. It develops BCT-100, an anti-cancer drug candidate, which is a recombinant human enzyme for the treatment of cancers that are dependent on arginine for growth. The company also develops chemical synthetic technology to produce polyethylene glycol; and mSPA-PEG, a bio-polymer used in the production of BCT-100 and other protein therapeutics. It has strategic partnerships with Morningside Asia and Kinexum. The company was founded in 2001 and is based in Shatin, Hong Kong.
Hong Kong Science Park
2 Science Park West Avenue
Room 511-513, 5/F
Founded in 2001
852 2521 1566
852 2521 1560
Key Executives for Bio-Cancer Treatment International Ltd.
Similar Private Companies By Industry
|Synco (HK) Limited||Asia|
|APC Pharmaceuticals & Chemical Ltd.||Asia|
|Spackman Group Limited||Asia|
|Venomics Pty Limited||Asia|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Germany, PA | Life TechnologiesPosted: Nov 22
- Frederick, MD | Computer Sciences Corporation (CSC)Posted: Nov 26
- Palm Harbor, FL | HCA Physician ServicesPosted: Dec 04
- Barceloneta, PR | AbbviePosted: Nov 28
Sponsored Financial Commentaries
To contact Bio-Cancer Treatment International Ltd., please visit www.bio-cancer.org. Company data is provided by Capital IQ. Please use this form to report any data issues.